The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.

Lantern Pharma Newsletter September 2022

In the second edition of the Lantern Pharma Newsletter you will find:

Phase 2 Harmonic™ clinical trial for LP-300 continues momentum with the activation of two cancer center sites and the launch of a patient-focused website
Lantern Pharma to host KOL webinar Sept. 22nd for Childhood Cancer Awareness Month
RADR® insights lead to accelerating the development of Actuate Therapeutics drug candidate Elraglusib
Scientific and investor conferences Lantern will be attending in Q3/Q4

Read More Download

This newsletter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events, our plans to advance the development of our drug candidates and antibody drug conjugate program, or our future financial performance. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this newsletter represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Lantern Pharma Newsletter September 2022

Harmonic™ Clinical Trial Updates

Lantern Pharma to Host KOL Webinar Sept. 22nd for Childhood Cancer Awareness Month

RADR® Insights Lead to Accelerating the Development of Actuate Therapeutics Drug Candidate Elraglusib

New Preclinical Data on LP-184 and LP-284 will Be Presented at Two Scientific Conferences in Q3

Lantern Pharma Management to Speak at Multiple Investor Conferences This Fall

Watch Panna’s Recent Interview on Bloomberg U.S. on the RedChip Money Report

Connect with us on Twitter and LinkedIn

Forward-Looking Statements

Join our Mailing List to get the latest Lantern news, sent right to your inbox